Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to "Hold"

Key Points

• Wall Street Zen downgraded Travere Therapeutics from “buy” to “hold,” even as the broader analyst view remains constructive with a consensus “Moderate Buy” rating and an average price target of $47.83.
• Recent quarterly results were strong on earnings: Travere posted EPS of $0.05, beating expectations of a loss, while revenue rose 55.6% year over year to $127.2 million despite missing revenue estimates.
• Insider selling has picked up, including sales by the CEO and another insider, though the transactions were made under pre-arranged 10b5-1 plans and partly tied to tax withholding obligations.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Saturday.

A number of other equities research analysts have also weighed in on the stock. Citigroup upped their target price on shares of Travere Therapeutics from $53.00 to $59.00 and gave the stock a "buy" rating in a report on Tuesday. Wedbush upped their target price on shares of Travere Therapeutics from $53.00 to $55.00 and gave the stock an "outperform" rating in a report on Tuesday. Canaccord Genuity Group upped their target price on shares of Travere Therapeutics from $47.00 to $56.00 and gave the stock a "buy" rating in a report on Tuesday, April 14th. Weiss Ratings lowered shares of Travere Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday. Finally, JPMorgan Chase & Co. lowered their target price on shares of Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating on the stock in a report on Wednesday, March 25th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $47.83.

Travere Therapeutics Trading Down 0.1%

TVTX opened at $42.60 on Friday. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70. Travere Therapeutics has a fifty-two week low of $13.88 and a fifty-two week high of $48.61. The firm has a market capitalization of $3.96 billion, a PE ratio of -185.21 and a beta of 1.13. The company's 50-day moving average is $32.83 and its 200 day moving average is $32.94.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The company had revenue of $127.20 million for the quarter, compared to analyst estimates of $136.23 million. During the same quarter in the prior year, the business posted ($0.47) EPS. The firm's revenue was up 55.6% compared to the same quarter last year. As a group, research analysts predict that Travere Therapeutics will post -0.24 earnings per share for the current fiscal year.

Insider Activity at Travere Therapeutics

In other news, insider Jula Inrig sold 2,174 shares of the firm's stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $46.65, for a total transaction of $101,417.10. Following the completion of the sale, the insider owned 113,549 shares in the company, valued at $5,297,060.85. This trade represents a 1.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric M. Dube sold 22,500 shares of the firm's stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total transaction of $988,875.00. Following the sale, the chief executive officer owned 432,886 shares of the company's stock, valued at approximately $19,025,339.70. The trade was a 4.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 400,015 shares of company stock worth $15,895,428 over the last 90 days. Corporate insiders own 4.44% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TVTX. Stephens Investment Management Group LLC purchased a new position in Travere Therapeutics in the 3rd quarter valued at approximately $38,232,000. State Street Corp grew its stake in Travere Therapeutics by 47.8% in the 4th quarter. State Street Corp now owns 4,756,666 shares of the company's stock valued at $181,752,000 after buying an additional 1,538,827 shares in the last quarter. Wellington Management Group LLP grew its stake in Travere Therapeutics by 3,331.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,201,469 shares of the company's stock valued at $28,715,000 after buying an additional 1,166,460 shares in the last quarter. Fiera Capital Corp purchased a new position in Travere Therapeutics in the 4th quarter valued at approximately $33,398,000. Finally, Perceptive Advisors LLC purchased a new position in Travere Therapeutics in the 2nd quarter valued at approximately $12,347,000.

Travere Therapeutics News Summary

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts remain bullish on Travere Therapeutics, with recent price target hikes to as high as $60 and continued Buy/Overweight ratings supporting the stock. Travere Therapeutics NASDAQ: TVTX Price Target Raised to $60.00
• Positive Sentiment: Q1 results beat EPS expectations and revenue grew 55.6% year over year, reinforcing the bullish analyst case and investor optimism. Travere Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation
• Positive Sentiment: Travere will present at several upcoming healthcare investor conferences, which could increase visibility and keep momentum around the stock. Travere Therapeutics to Participate at Upcoming Investor Conferences
• Neutral Sentiment: The company priced an upsized $475 million convertible senior notes offering to refinance 2029 notes, improving balance-sheet flexibility but creating potential future dilution. Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
• Neutral Sentiment: HC Wainwright trimmed earnings estimates slightly but kept a Buy rating and a $57 target, so the outlook remains supportive overall. Wells Fargo & Company Issues Positive Forecast for Travere Therapeutics NASDAQ: TVTX Stock Price
• Negative Sentiment: Multiple insiders, including the CEO, CFO, directors, and executives, disclosed recent stock sales, which can create near-term concern even though many were tied to tax withholding and 10b5-1 plans. Jula Inrig Sells 20,000 Shares of Travere Therapeutics NASDAQ: TVTX Stock

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.